ArticleTargeted oncology2021

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.

Domenica Lorusso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.